Zenas BioPharma ZBIO 深 沪
等待开盘 10-21 09:30:00 美东时间
28.18
+1.470
+5.50%
华盛通- 最 高29.705
- 今 开26.38
- 成交量 54.90万股
- 最 低 26.38
- 昨 收 26.71
- 总市值 18.37亿
- 52周最高 44.60
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 13.50
- 委 比 -43.34%
- 总股本 6517.67万
- 历史最高 44.60
- 量 比 0.99
- 振 幅 12.45%
- 历史最低 5.83
- 每 手 1
- 风险率 6.64%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Zenas BioPharma Presents New Obexelimab Data In Immunoglobulin G4-Related Disease At 6th International Symposium On IgG4-Related Disease
– Phase 3 INDIGO open-label extension findings demonstrated sustained clinical activity of obexelimab – – Additional analyses of secondary endpoints showed that significantly fewer patients experienced clinically meaningful cumulative glucocorticoid toxicity at week 52 – – Initial open-label extensi...
10-12 19:07
Zenas BioPharma Announces the Presentation of New Obexelimab Data in IgG4-Related Disease at the 6th International Symposium on IgG4-Related Disease
Zenas BioPharma announced new data on obexelimab for IgG4-RD, showing sustained flare protection, reduced glucocorticoid toxicity, and preserved vaccine responses during a treatment-free window. The Phase 3 INDIGO open-label extension demonstrated a 93% probability of remaining flare-free at 12 months and significantly fewer patients experiencing glucocorticoid toxicity. Initial vaccine sub-study results indicated robust immune responses to influ...
10-12 11:00
Zenas BioPharma to Host Virtual R&D Event
Zenas BioPharma will host a virtual R&D event on October 27, 2026, to discuss its pipeline, including obexelimab (a bifunctional monoclonal antibody for systemic lupus erythematosus) and ZB021 (an oral IL-17AA/AF inhibitor). Dr. Joseph F. Merola will provide insights into the biology and clinical considerations. The event will include presentations by the management team and a live webcast available on the company's website.
10-06 11:05
美股大行评级 | 潜在涨幅600.93%！Ascendiant Capital上调Aytu BioPharma目标价至15美元，维持"买入"评级
今日重点评级关注：Ascendiant Capital：维持Aytu BioPharma"买入"评级，目标价从14.5美元升至15美元；摩根大通：维持Annexon"超配"评级，目标价从14美元升至15美元
10-01 19:18
HC Wainwright & Co. Reiterates Buy on Zenas BioPharma, Maintains $44 Price Target
HC Wainwright & Co. analyst Matthew Caufield reiterates Zenas BioPharma (NASDAQ:ZBIO) with a Buy and maintains $44 price target.
09-30 18:29
Zenas BioPharma To Present New Data From Phase 3 INDIGO Trial Evaluating Obexelimab In IgG4-RD At 6th International Symposium On IgG4-Related Disease, And ACR Convergence 2026
– New data from the Phase 3 INDIGO open-label extension will include the longer-term flare protection and safety data of obexelimab in IgG4-RD – – Additional analyses will assess glucocorticoid-associated toxicity and vaccine responses – WALTHAM, Mass., Sept. 22, 2026 (GLOBE NEWSWIRE) -- Zenas BioPh...
09-22 19:15
Zenas BioPharma Announces Upcoming Presentations of Obexelimab Data in IgG4-Related Disease at the IgG4ward! 6th International Symposium on IgG4-Related Disease and ACR Convergence 2026
Zenas BioPharma announced that new data from the Phase 3 INDIGO trial evaluating obexelimab in IgG4-RD will be presented at the 6th International Symposium on IgG4-Related Disease and ACR Convergence 2026. The presentations will include longer-term flare protection and safety data, as well as analyses of glucocorticoid-associated toxicity and vaccine responses in patients treated with obexelimab. These findings aim to advance understanding of the...
09-22 11:05
Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Zenas BioPharma granted stock options and restricted stock units to new employees as inducement grants under Nasdaq rules. The stock options, exercisable at $31.93 per share, vest over four years, with 25% on the first anniversary and the remainder in monthly installments. RSUs vest in four equal annual installments. Both grants are subject to continued employment and governed by the 2026 Inducement Plan. Zenas focuses on developing therapies for...
09-18 20:15
Zenas BioPharma Registers Resale Of Up To 7M Shares By Selling Stocholder
ZENAS BIOPHARMA, INC.Up to 7,000,000 Shares of Common Stock This prospectus relates to the resale or other disposition from time to time of up to 7,000,000 shares (the "Shares") of our common stock, par value $0.0001 per share (the "Common Stock"), by the selling stockholder (the "Selling Stockhol...
09-12 04:52
Zenas BioPharma to Present at Upcoming Healthcare Investor Conferences
Zenas BioPharma announced that its management will present at three upcoming investor conferences: the Citi Biopharma Back to School Conference on September 9, 2026, the Morgan Stanley 24th Annual Global Healthcare Conference on September 14, 2026, and the H.C. Wainwright 28th Annual Global Investment Conference on September 16, 2026. The company, focused on developing therapies for autoimmune and inflammatory diseases, is advancing two late-stag...
09-04 11:05
